ScreenerHero

GRCEGrace Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · gracetx.com
2.200USDMkt Cap: 46.28M $P/E: —

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap46.28M $
Enterprise Value31.26M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-7.79M $
Revenue/Share—
Last Price2.200 USD
Fiscal Year EndMar 2026
MR QuarterJun 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.65
PEG—
EV/EBITDA-3.02
EV/Revenue—
P/S—
P/B0.72
EPS (TTM)-1.17
EPS (Forward)-0.46
52W Range
2.15063% of range2.230
52W High2.230 USD
52W Low2.150 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-12.20%
ROA-11.69%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.87M $
CapEx (TTM)—
FCF Margin—
FCF Yield-14.69%
Net Debt-13.76M $
Net Debt/EBITDA1.33
Balance Sheet
Debt/Equity—
Current Ratio11.47
Quick Ratio11.02
Book Value/Sh2.962 USD
Cash/Share0.6540 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:6
Split DateJul 10, 2023
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)6.055 USD
Upside (mean)+175.2%
Target Range4.027 USD – 8.083 USD
$4.027+175.2% to mean$8.083
# Analysts2
Ownership
Shares Out.21.04M
Float15.61M
Insiders18.20%
Institutions31.39%
Short Interest
Short Ratio6.5d
Short % Float11.40%
Short % Out.9.77%
Shares Short1.59M
Short (prev mo.)1.71M
Technical
SMA 502.282 (-3.6%)
SMA 2003.130 (-29.7%)
Beta—
S&P 52W Chg21.00%
Avg Vol (30d)75.90K
Avg Vol (10d)164.17K
Technical Indicators
RSI (14)49.8
MACD-0.0401
MACD Signal-0.0563
MACD Hist.+0.0162
BB Upper2.264 USD
BB Middle2.141 USD
BB Lower2.018 USD
BB Width11.45%
ATR (14)0.1204 USD
Vol Ratio (20d)0.30x